ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S.

As of June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. carries a market capitalization of 5.96B, placing it among publicly traded companies globally. Its enterprise value stands at 6.11B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. has 23.85M shares outstanding.

As of June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. trades at a trailing price-to-earnings ratio of 82.56. The price-to-sales ratio is 7.43, and the price-to-book ratio stands at 11.81.

As of June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. trades at an EV/EBITDA multiple of 20.52 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 7.62 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 25.62 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. trades at an EV/FCF ratio of 274.96, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 6.11B versus a market cap of 5.96B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. maintains a current ratio of 2.09, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 35.26, indicating elevated leverage, while an interest coverage ratio of 5.48 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. posted a return on equity (ROE) of 17.40, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 26.17 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.44, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 19.34, useful for judging operating efficiency across full business cycles. The company generates approximately 2.12M in revenue per employee across its workforce of 379.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.05 indicates how many times ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. recorded 50.58M in income tax expense. That works out to an effective tax rate of 41.19, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 122.80M, leaving 72.22M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S.'s stock has declined approximately 48.85% over the past 52 weeks. The 50-day moving average sits at 150.63, while the 200-day moving average is 244.53.

Over the twelve months ended June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. generated 802.27M in revenue and converted that into 72.22M in net income, yielding earnings per share of 3.03. EBITDA reached 297.74M, while operating income came in at 245.63M.

As of June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. holds 30.10M in cash and equivalents against 178.05M in total debt, resulting in a net debt position of 94.72M. Total book value stands at 505.01M, with working capital of 286.79M providing operational flexibility.

ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. produced 98.31M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -108.03M in capital expenditures, free cash flow totaled -9.72M - equivalent to -0.41 per share.

Over the twelve months ended June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. posted a gross margin of 55.67, reflecting its pricing power and cost economics. The operating margin of 30.62 and net profit margin of 9.00 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.16: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches 0.33, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. shareholders.

As of June 30, 2026, ONCOSEM ONKOLOJIK SISTEMLER SANAYI VE TICARET A.S. has an Altman Z-Score of 10.77, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.